Atlas Trials

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

Clinical trial NCT06614231 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06614231
Sponsor
Sun Yat-sen University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC, Stage IIIANSCLC (non-small Cell Lung Cancer)
Start date
2024-09-20
Primary completion
2028-09-08
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.